Skip to main content

Table 5 Tacrolimus pharmacokinetic data in relation to CYP3A5 and SXR A7635G gene polymorphisms in the 49 patients of the study

From: CYP and SXR gene polymorphisms influence in opposite ways acute rejection rate in pediatric patients with renal transplant

  Days CYP3A5*3 SXR A7635G
AA/AG (12 patients) GG (37 patients) AA (16 patients) AG (24 patients) GG (9 patients)
Dose/kg (mg/kg) day 7 0.17 ± 0.10 0.15 ± 0.06 0.18 ± 0.10 0.14 ± 0.04 0.16 ± 0.06
day 30 0.18 ± 0.10 0.13 ± 0.06 0.17 ± 0.11 0.14 ± 0.05 0.14 ± 0.07
day 90 0.15 ± 0.09 0.11 ± 0.06 0.14 ± 0.10 0.10 ± 0.05 0.12 ± 0.07
day 180 0.13 ± 0.08 0.09 ± 0.06 0.11 ± 0.09 0.08 ± 0.04 0.11 ± 0.07
day 360 0.11 ± 0.08 0.07 ± 0.05 0.10 ± 0.08 0.07 ± 0.03 0.08 ± 0.07
C0/(dose/kg) (ng/ml)/(mg/kg) day 7 67.52 ± 48.67* 80.67 ± 58.46 95.47 ± 82.73 64.13 ± 24.06 79.11 ± 53.07
day 30 73.83 ± 105.88* 111.45 ± 70.37 103.21 ± 87.98 97.40 ± 60.02 111.86 ± 118.66
day 90 92.19 ± 139.61* 114.52 ± 68.18 103.33 ± 76.67 108.79 ± 64.90 119.26 ± 157.82
day 180 70.48 ± 137.70* 137.70 ± 103.44 121.30 ± 101.09 127.20106.22 104.06 ± 70.10
day 360 72.56 ± 182.92* 182.92 ± 199.75 192.34 ± 283.35 142.93 ± 103.30 121.24 ± 78.97
  1. Data are expressed as mean ± S.D. * p-value < 0.05 at Mann Whitney test